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Abstract
Gaucher’s disease is a rare genetic lysosomal storage disorder. People suffering from
Gaucher’s disease do not have functional beta-glucocerebrosidase (GBA), which results in toxic
build-up of undegraded substrates within the cell. Currently, patients living with this disease rely
on biologics to reduce their symptoms, however, they require frequent transfusions and are
incapable of crossing the blood brain barrier (BBB) to address neurologic symptoms of the
disease. To evaluate the efficacy of novel biologic therapeutics, a human Gaucher’s disease
model is required. Here, we have utilized near-haploid human cells (Hap1) modified via
CRISPR-Cas9 to model Gaucher’s disease in vitro. These cells contain a 479 bp insertion in the
6th exon of the GBA gene, resulting in non-functional GBA. PCR, enzyme activity assays, and
flow cytometry have been employed to confirm the diseased genotype and phenotype.
Characterization of GBA knock-out cells shows a total loss of GBA enzyme activity. Further
characterization demonstrates a normal growth rate but an increased number of lysosomes,
indicating a diseased phenotype. After confirmation of the diseased genotype and phenotype in
this Hap1 GBA knock-out (KO) cell line, the diseased cells were treated with recombinant
human GBA to determine their response. Evaluating the Hap1 GBA KO cells’ response to
existing recombinant GBA enzyme shows the promise of utilizing this cell line to evaluate novel
therapeutics for the disease.
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1. Introduction
1.1 Motivation
Gaucher’s disease is a rare genetic disorder caused by mutations in the GBA gene. Mutations
in this gene results in non-functional beta-glucocerebrosidase (GBA), which causes a toxic
buildup of waste within cells [1]. As this disease is the result of a non-functioning enzyme,
biologic drugs are an option for treatment. Currently, enzyme replacement therapy (ERT) is
available to help prevent permanent damage to tissues and to mitigate symptoms [2].
Unfortunately, biologic drugs, such as enzymes, tend to be unstable and have a short half-life in
the body [3]. To attempt to ameliorate these issues, utilizing extracellular vesicles, specifically
exosomes, to deliver the ERT may be feasible.
To evaluate the efficacy of traditional ERT and as well as novel exosome-based therapeutics
in vitro, a disease model must be established and characterized. Using genetic engineering, the
GBA gene can be knocked out in order to model the lack of GBA. After performing genotypic
and phenotypic analysis of the disease model, the effect of supplementing the cells with
recombinant GBA must be characterized in order to determine whether the cell line would be an
appropriate model to evaluate new, exosome-based therapeutics.

1.2 Background
Lysosomal storage diseases (LSDs) are a group of genetic disorders that prevent proper
functioning of the lysosome. One of the most common of these diseases is Gaucher’s disease,
which occurs in 2 out of 100 000 individuals [4]. It occurs when a mutation in the GBA gene
results in non-functional beta-glucocerebrosidase, leading to an accumulation of
glycosphingolipids in the lysosomes of phagocytes, particularly macrophages [4]. Type 1
Gaucher’s disease is the most common form of the disease and it does not affect the central
nervous system [1]. Common symptoms of type 1 disease include an enlarged liver and spleen,
anemia, easy bruising, lung diseases, fractures, and arthritis [1]. Types 2 and 3 affect the brain
and spinal cord, adding seizures, abnormal eye movement, and brain damage to the type 1
symptoms [1]. Current treatments consist of enzyme replacement therapy (ERT) or substrate
reduction therapy (SRT). Currently, three recombinant forms of GBA are approved ERT for
Gaucher’s disease [5]. These drugs are delivered via intravenous injection, often every two
weeks. While ERT is effective at reducing symptoms of type I of the disease, enzymes cannot
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cross the blood brain barrier (BBB) on their own and therefore cannot reach the affected brain
tissue in types 2 and 3.
Utilizing extracellular vesicles, specifically exosomes, to deliver active GBA may address
some of the current downsides to ERT. Exosomes are nano-scale vesicles derived directly from
cells and are capable of shuttling different types of cargo, including proteins [6]. Previously, our
lab has shown the ability to load active GBA onto exosomes utilizing the transmembrane protein,
VSVG [6]. Using these exosomes allows for targeted delivery of GBA to the endocytic
compartment (the natural location of GBA) and may allow for delivery across the BBB [6].
While it was shown that these exosomes are capable of increasing the GBA activity within cells
to which they were delivered, these cells already had a healthy level of enzyme, rather than
mimicking a diseased state [6].
To perform preliminary testing on new therapeutics for Gaucher’s disease, a disease model
must be used. Transgenic mice models are frequently used in pre-clinical studies; however,
studies have shown mice are not capable of fully mimicking human disease and may be the
reason why many therapeutics fail when they reach human clinical trials [7]. The underlying
molecular cause of a certain disease, such as sepsis, is fundamentally different in mice and
humans [7]. Several mouse models of Gaucher’s disease exist, some which chemically induce
the disease and others which are genetically engineered. Unfortunately, most of these mouse
models have significant drawbacks. For example, the N70S point mutation was induced in mice
due to its association with type I disease in humans [8]. Yet in mice, this point mutation did not
reduce GBA activity and rather resulted in a skin defect causing the animals to die within 24
hours of birth [8]. Other conditional knock-out mouse models have been more successful in
modelling the disease and assisting in efficacy studies, however, many of these modified mice
have a limited lifespan (maximum three weeks) or do not accurately represent a mutation found
in humans with Gaucher’s disease [8]. To improve the ease of pre-clinical testing and reduce the
number of mice needed to study the effects of new therapies, a cell line disease model may be an
improvement.
With the advancement of genome engineering technologies, such as CRISPR-Cas9, it is both
simple and feasible to knock-out genes to model diseases in established human cell lines in vitro.
CRISPR-Cas9 utilizes a combination of a short gRNA sequence to target the desired region of
the genome and a Cas9 nuclease (isolated from streptococcus pyogenes) to induce a double
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stranded break [9]. This form of genome engineering is simpler than ZFNs or TALENs, as only
the short 20 nucleotide gRNA has to be changed with each new target [9]. While off-target edits
are a concern when using a CRISPR-Cas9 system, cells can be screened for the desired diseasecausing mutation prior to establishing a stable knock-out cell line.
Unfortunately, the diploid nature of human cells complicates genetically engineering knockout cell lines. In order to completely knock-out a gene, both copies must be targeted and edited.
Haploid human cell lines, such as the near-haploid cell line Hap1, address this issue. Hap1 cells
arose from near-haploid myeloid leukemia cells (KBM7) [10]. When treated with common
pluripotency factors OCT4, SOX-2, c-MYC, and KLF4, the previously non-adherent KBM7
cells were found to be haploid, absent of all hematopoietic markers, and adherent, creating the
Hap1 cell line [10]. Since these cells were discovered, they have become a workhorse cell line
for disease modelling.

1.3 Project Goals
Ultimately, the goal of this project is to show the feasibility of using a Gaucher’s disease
model to evaluate the efficacy of biologic therapeutics in vitro. To do this, first the genotype and
phenotype of the Hap1 Gaucher’s disease model must be characterized to confirm a lack of GBA
activity. The genotype can be confirmed via PCR, while the phenotype can be confirmed via
enzyme activity assays and cell morphology. The diseased phenotype can also be related to the
number of lysosomes accumulating within the cell, which can be observed via confocal
microscopy and quantified using flow cytometry. Next, the Hap1 GBA knock-out cells’ response
to treatment with recombinant human GBA (rhGBA) must be analyzed to determine whether it is
a suitable cell line for pre-clinical efficacy studies for biologic therapeutics for the disease.

2. Materials and Methods
See supplementary material S.1 for a complete list of chemicals and reagents.

2.1 GBA Knockout in Hap1 Cells
Hap1 GBA knock-out cell line was generated by Horizon Discovery (Cambridge, UK) via
CRISPR-Cas9. The guide RNA sequence, TCCATTGGTCTTGAGCCAAG, targeted exon 6 of
the GBA gene and a 479 bp donor template was provided to disrupt the enzyme’s coding
sequence. See supplementary material S.2 for the full donor sequence.
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Figure 1. Schematic of donor sequence knock-in in the 6th exon of the GBA gene. Insertion of
donor template results in non-functional GBA.
Hap1 cells were screened for the desired insertional mutation using Sanger sequencing
(sequencing primer: AAGTGATAAGCAGAGTCCCATACTC). The Hap1 GBA KO cells
passed the genetic characterization and were also analyzed for viability and mycoplasma
contamination.

2.2 Hap1 Lysosome Staining
Lysosomal Stain:
1. Dilute stock LysoTracker Red DND 99 (ThermoFisher, Fremont CA, USA) to 50nM
working concentration.
2. Warm appropriate volume of staining solution for intended cell culture well.
3. Remove old medium and replace with staining solution.
4. Incubate for 30 minutes.
5. Replace staining solution with PBS and image immediately or proceed to flow cytometry
analysis.
Flow Cytometry Analysis:
1. Aspirate staining solution from cells.
2. Wash cells 3x with pre-warmed PBS.
3. Add 0.05% trypsin (VWR, Radnor PA, USA) to plate and incubate at 37°C for 5-7
minutes.
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4. Deactivate trypsin by adding 3x the volume of cell culture media. Collect cells and
centrifuge at 1500rpm for 5 minutes.
5. Aspirate media from microcentrifuge tube.
6. Resuspend cell pellet in PBS.
7. Filter resuspended cells through a 40um cell strainer (Corning, Corning NY, USA) to
remove large cellular debris or clumps of cells.
8. Load glass test tube containing strained cells into the flow cytometer and run the
instrument.

2.3 Genomic DNA Extraction and PCR
1. Collect 1mL of resuspended cells after passaging. Subject to 2-3 freeze-thaw cycles in the
-80°C freezer to lyse.
2. Extract genomic DNA utilizing Bio-Rad InstaGene Matrix (Bio-Rad; Hercules CA,
USA).
a. Centrifuge lysed cells at 12 000 rpm for 1 minute.
b. Resuspend cells in PBS and centrifuge at 12 000 rpm for 1 minute.
c. Resuspend cells in 20ul of sterile water and add to 200ul of InstaGene Matrix.
d. Incubate in a 56°C water bath for 20 minutes, removing the tube to vortex and
resuspend matrix every 5 minutes.
e. Vortex for 10 seconds at high speed.
f. Incubate tube in a boiling water bath for 8 minutes.
g. Vortex for 10 seconds at high speed.
h. Spin down at 12 000 rpm for 3 minutes.
i. Extracted DNA is in the supernatant.
3. Create PCR reaction.
a. Add 25ul of 2x Taq Master Mix (GenScript; Piscataway, NJ, USA).
b. Add 1ul of each 10uM primer (forward and reverse).
i. Forward primer: CTGATGGAGTGGGCAAGAT
ii. Reverse primer: AAGTGATAAGCAGAGTCCCATACTC
c. Add 10-20ul of DNA template (supernatant from step 2).
d. Fill with nuclease-free water up to 50ul.
4. Place PCR tube in a thermocycler and run the following program:
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Segment

# of Cycles

Temperature

Time

1

1

95°C

2 minutes

2

40

95°C

30 seconds

Tm- 5°C

20 seconds

72°C

1 minute/kb of dsDNA

3

1

72°C

7 minutes

4 (optional)

1

4°C

Hold

2.4 GBA Enzyme Activity Assay
Hap1 Cell Seeding and rhGBA Treatment
1. Seed Hap1 cells in a 96-well plate.
2. After 24H of cell growth, add 50 ng, 100 ng, or 150 ng of rhGBA to cultured cells.
3. Incubate at 37°C for one hour.
4. Remove cell culture media and wash 1x with pre-warmed PBS.
5. Add 100ul of reporter lysis buffer (Promega, Madison WI, USA) to each well and shake
plate at high speed until cells begin to lift off of plate.
6. Collect cells from each condition and place in microcentrifuge tubes. Subject to one
freeze-thaw cycle at -80°C.
7. After thawing slowly to promote cell lysis, proceed to sample preparation and activity
assay.
Buffer Preparation:
Store all buffers at 4°C
1. 0.1M sodium citrate, pH 6.0: Dissolve 301 mg of sodium citrate dihydrate (MW 294.11
g/mol)) and 284 mg of citric acid (MW 192 g/mol) into 20 ml diH2O. Adjust pH to 6.0
with 1M NaOH or 1M HCl. Fill up the container to 25 ml mark with diH2O.
2. 464 mM sodium cholate: Dissolve 2 g sodium cholate (MW 430.55 g/mol, Sigma
Aldrich) into 10 ml diH2O.
3. 1mM DTT: Dilute 1ul 1M DTT in 999ul diH20.
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4. Assay buffer: Mix 323 ul of 464mM sodium cholate with 3 ml of 0.1M sodium citrate.
Allow to incubate at room temperature for 5 minutes. Add DI water to 6 ml. Add 30 ul of
1M DTT immediately before buffer is used. Mix gently and work promptly.
5. Stop buffer: Add 0.938 g of glycine (MW 75.07 g/mol,) and 0.299 g of sodium hydroxide
(MW 40 g/mol) into 10 ml diH2O. Adjust to pH 10, then fill to with DI water to 25 ml.
Sample Preparation:
1. Positive control: Make 1 ml of 0.4 ng/ul rhGBA protein (R&D systems, Minneapolis
MN, USA) solution. Gently invert to mix.
2. Assay substrate: Make 6 mM substrate by dissolving 2 mg of 4-Methylumbelliferyl β-Dglucopyranoside into 1 ml of assay buffer. Mix gently without agitating. Trace amounts
of solid may not dissolve.
Activity Assay:
1. Using a 96-well plate, load 25 ul of cell lysate or positive control into the appropriate
wells.
2. Add 25ul of assay substrate into each well. Create a blank well by adding 25ul of assay
substrate and 25ul of assay buffer.
3. Cover the plate with a lid and nutate for 30 seconds to mix.
4. Incubate at room temperature for 20 minutes.
5. Add 50ul of stop buffer to each well to stop the reaction.
6. Read fluorescence intensity using a plate reader (excitation: 365 nm, emission: 445 nm).

3. Results
3.1 Disease Model Morphology and Growth
The morphology of WT Hap1 cells and GBA KO cells was compared to determine
whether the modified cells exhibited any visual characteristics of disease. 24 hours after seeding
the cells on a 10cm dish, there was no visible difference in the morphology of control Hap1 cells
and Hap1 GBA KO cells, as shown in Figure 2 A). To further investigate the health of the
diseased cells in culture, their growth rate was observed over a period of 72 hours. During this
time period, the growth rate of both the control Hap1 and Hap1 GBA KO cell lines was found to
be similar, suggesting that the GBA KO cells can be propagated in culture for biologic drug
testing.
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Figure 2. A) Phase contrast images of Hap1 control and Hap1 GBA KO cells, taken at 10x
magnification 24 hours after seeding. B) Comparison of Hap1 and Hap1 GBA KO growth rates.
Error bars represent standard deviation (n = 3).

3.2 Hap1 GBA KO Genotype and Phenotype
To confirm the diseased state in the GBA KO cells, the genotype and phenotype were
studied. PCR analysis shows the desired mutation in the GBA gene; to knock-out the gene, a 479
bp sequence was inserted in the 6th exon, inducing frameshift mutations and preventing normal
GBA from being transcribed. This insertion results in a 1236 bp band after undergoing PCR, as
shown in figure 3 A).
To confirm that this insertional mutation has knocked out GBA, the enzyme activity itself
was evaluated in both the healthy, control Hap1 cells and the Hap1 GBA KO cells. Compared to
the control cells, Hap1 GBA KO cells had only 4.3% of the GBA activity of normal cells, as
shown in figure 3 B).
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Figure 3. A) DNA gel electrophoresis of amplified Hap1 and Hap1 GBA KO DNA. 757 bp band
is the expected size of the unmodified gene’s fragment between the primers. Larger bands (1236
bp) are expected size of the region targeted by the primers plus the insertional mutation (479 bp)
leading to KO. B) GBA enzyme activity of Hap1 and Hap1 GBA KO cells. Error bars represent
the standard deviation (n = 3).
Hap1 GBA KO cells also showed increased accumulation of lysosomes, as shown in
figure 4 A) via staining with LysoTracker Red. LysoTracker Red is an acidotrophic reagent that
stains cellular compartments with acidic interiors [11]. Such acidic compartments include
lysosomes, late endosomes, and autophagosomes [11]. Normally, endosomes and
autophagosomes fuse with lysosomes, forming autolysosomes and endolysosomes where
substrates are degraded [11]. In cells with Gaucher’s or other lysosomal storage diseases,
substrates within these autolysosomes and endolysosomes cannot be degraded, resulting in their
accumulation [11]. The increase in red-stained compartments in the Hap1 GBA-KO cells is
consistent with this expected diseased phenotype.
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Figure 4. A) Lysosomes stained with LysoTracker Red in Hap1 and Hap1 GBO KO cell lines.
Images taken at 40x. B) Flow cytometry analysis of lysosomal accumulation. Increased PE-A
intensity associated with increased number of lysosomes.
To quantify the accumulation of lysosomes, Hap1 and Hap1 GBA KO cells stained with
LysoTracker Red were analyzed via flow cytometry. As shown in figure 4 B), the observed mean
fluorescence of Hap1 GBA KO cells was shifted right compared to healthy Hap1 cells. This
confirms the visual findings shown in figure 4 A).

3.3 rhGBA Treatment Efficacy
Hap1 GBA KO cells were treated with rhGBA in order to evaluate their dose dependent
response. As shown in figure 5, when either 100ng or 150ng of rhGBA was added to 96-well
cultures of Hap1 GBA KO cells, both conditions had a significant increase in enzyme activity
compared to the untreated control. The 150ng dose condition was found to have a statistically
similar level of GBA activity as the healthy Hap1 cells. While the 100ng treatment did not
restore Hap1 GBA KO cells to WT Hap1 enzyme activity levels, this dose was also found to
significantly increase the GBA activity compared to untreated controls. This data suggests that
GBA activity in the diseased cells can be restored to normal levels with ERT treatment.
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Figure 5. Hap1 GBA KO response to treatment with rhGBA (50ng, 100ng, and 150ng doses).
GBA enzyme activity increases with dose. Error bars represent standard deviation (n = 3).

4. Discussion
By studying the genotype and phenotype of the Hap1 GBA KO cell line, it has been
shown that this cell line is a reliable model of Gaucher’s disease. This cell line exhibits both an
accumulation of lysosomes and a significantly decreased GBA activity compared to healthy
Hap1 cells, which are hallmark phenotypic abnormalities of Gaucher’s cells. Most importantly,
the Hap1 GBA KO cells showed a dose-dependent response to treatment with rhGBA. This
response to ERT indicates that this cell line can be used to evaluate novel therapeutics to treat
Gaucher’s disease.
Simple maintenance and culture of Hap1 cells makes them feasible to maintain
throughout the duration of pre-clinical in vitro studies. They are an adherent cell line with no
special requirements for growth media (see S.3 for culture method) and maintain stable growth
for approximately 20-30 passages. In this study, the Hap1 GBA KO cells were found to
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proliferate at a statistically similar rate to the WT Hap1, showing that the disease model can be
cultured alongside a healthy control without any special considerations for disparate growth
rates.
In future studies, this disease model can be utilized to evaluate the efficacy of our
previously reported exosome-based therapy for Gaucher’s disease [6]. The loading of GBA onto
exosomes and its bioactivity has been previously reported [6]. While current ERT is effective for
patients with type 1 Gaucher’s disease, naked enzyme cannot cross the BBB to address
neurological manifestations of the disease. Studies have shown that exosomes are capable of
crossing the BBB [12] [13]. Utilizing exosomes as a delivery vehicle for GBA is expected to
enhance the delivery of GBA to the brain tissue. Exosomes are also capable of delivering GBA
to its natural location within the cell. Exosomes frequently enter the cell via endocytosis, which
results in their cargo being deposited to the endosomal pathway [14]. In this pathway, the
contents of the exosome can be transferred from early endosome, to late endosome, and finally to
the lysosome [14]. Ideally, this targeted delivery should result in significant enhancement of
GBA activity in Hap1 GBA KO cells at either similar or lower doses than pure, recombinant
enzyme.

5. Conclusion
This study has demonstrated the feasibility of utilizing genetically modified cell lines as
disease models for pre-clinical testing of novel biologic drugs. Haploid human cells can be
modified using genetic engineering tools, such as CRISPR-Cas9, to knock-out genes and model
human diseases in vitro. In this study we have successfully characterized a Hap1 GBA KO cell
line and confirmed that it mimics both the genotype and phenotype of the lysosomal storage
disorder, Gaucher’s disease. This study has also confirmed that this cell line has a dosedependent response to ERT, showing that it is possible to use this cell line to test the effect of
novel enzyme therapeutics and their effect on intracellular enzyme activity. In future studies, the
aim is to use this cell line to further study a previously reported exosome-based GBA delivery
system and its feasibility as an improved ERT.
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Supplementary Material
S.1 Complete List of Reagents
Table 1: List of Reagents
Reagent

Company

Product Number

Associated
Procedure

Hap1 GBA KO Cell

Horizon Discovery

HZGHC002786c001

Line

2.1 GBA Knockout in
Hap1 Cells

LysoTracker Red

ThermoFisher

DND-99

Scientific

InstaGene Matrix

BioRad

L7528

2.2 Hap1 Lysosomal
Staining

7326030

2.3 Genomic DNA
Extraction and PCR

Custom Primers

IDT

N/A

2.3 Genomic DNA
Extraction and PCR

2x Taq Master Mix

GenScript

E000019

2.3 Genomic DNA
Extraction and PCR

Reporter 5x Lysis

Promega

E3971

Buffer
rhGBA

2.4 GBA Enzyme
Activity Assay

R&D Systems

7410-GHB-020

2.4 GBA Enzyme
Activity Assay

1M NaOH

Sigma Aldrich

S5881

2.4 GBA Enzyme
Activity Assay

0.1M Sodium Citrate

Sigma Aldrich

W302600

Dihydrate
Citric Acid

2.4 GBA Enzyme
Activity Assay

Sigma Aldrich

251275

2.4 GBA Enzyme
Activity Assay

Sodium Cholate

Sigma Aldrich

C6445

2.4 GBA Enzyme
Activity Assay

DTT

Sigma Aldrich

10197777001

2.4 GBA Enzyme
Activity Assay

16

Glycine

VWR

56-40-6

2.4 GBA Enzyme
Activity Assay

4-Methylumbelliferyl

Sigma Aldrich

M3633-250MG

β-D-glucopyranoside
FBS

2.4 GBA Enzyme
Activity Assay

GE Healthcare

SH30088.03H1

S.2 Cell Culture
Method

IMDM

ThermoFisher/Gibco

12440061

S.2 Cell Culture
Method

0.05% Trypsin

VWR

45001-082

S.2 Cell Culture
Method

Penicillin

ThermoFisher/Gibco

15140163

Streptomycin (PS)

S.2 Cell Culture
Method

S.2 Hap1 GBA KO Donor DNA Sequence
The following is the donor DNA sequence inserted into exon 6 of the GBA gene at
chr1:55238211.
TGTGGCAACCGCTGAATATCGCCACCACCAGCGTGCTGCTGACGCTGGCCGATAACGACACGCC
GGTGTGGCTTTCTACCCCATTAAATAACGATATCGTCAACCAGAGCCTGCGTTTTCATACCAAC
GCGCCGCTGGTCAGCCAGCCGGAACAGGCGACCTTCGCGGTGACGGATGAGGCGATTTCCAGCG
AACAGCTCAACGCCCTTTCCACCGGCACCGCCGTTGCGCCGGAAGCGGGTGCGACGCTGATTTT
ACAGGTCGCCAGCCTGAGCGGCGGACGCATGTTGCGCCTTACTGGTGCGGGTATTGCCGAAGAA
CGAATGATCGCTCCGCAGCTGCCGAAGTGCATTCTGCACGAACTCACCGAGCGCCCGCATCCGT
TCCCGCTCGGCATCGACCTGATCCTGACCTGTGGCGAGCGCCTGCTGGCTATTCCGCGAACCAC
TCATGTGGAGGTGTGCTGATGTACGTTGCCG
This sequence was incorporated into the genomic DNA after the cas9 double-stranded break via
non-homologous end joining (NHEJ).
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S.3 Cell Culture Method
Preparing Media:
1. Add 50ml of FBS (GE Healthcare, Chicago IL, USA) to a 500ml bottle of IMDM
(ThermoFisher, Fremont CA, USA).
2. Add 5ml of PS (ThermoFisher, Fremont CA, USA) to the combined FBS and IMDM.
Mix well.
3. Aliquot as desired and store at 4°C.
Passaging Hap1 Cells:
Passage Hap1 cells every 2-3 days, up to passage #30. Perform all steps under sterile conditions.
1. Aspirate depleted media
2. Wash with 3 mL of PBS. Pipet gently into side of plate.
3. Aspirate PBS.
4. Add 1.5 mL of trypsin (VWR, Radnor PA, USA) to plate and incubate at 37°C for 2
minutes.
5. Deactivate trypsin (VWR, Radnor PA, USA) with 4.5 mL of IMDM + 10% FBS + PS
media.
6. Collect media in 15 mL centrifuge tube, spin at 1500 RPM for 5 minutes.
7. Aspirate off supernatant.
8. Resuspend the pellet in IMDM + 10% FBS + PS media.
9. Plate at desired density.
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